Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings

Potential care gaps in the cervical cancer screening process among women diagnosed with cervical cancer in an era with increased human papillomavirus (HPV) testing have not been extensively evaluated.

[1]  Yenan Zhu,et al.  Assessment of US Preventive Services Task Force Guideline–Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019 , 2022, JAMA network open.

[2]  D. Coffey,et al.  False-negative Papanicolaou tests in women with biopsy-proven invasive endocervical adenocarcinoma/adenocarcinoma in situ: a retrospective analysis with assessment of interobserver agreement. , 2021, Journal of the American Society of Cytopathology.

[3]  N. Wentzensen,et al.  Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities , 2021, Preventive Medicine.

[4]  C. Kennedy,et al.  HPV self-sampling for cervical cancer screening: a systematic review of values and preferences , 2021, BMJ Global Health.

[5]  R. Leach,et al.  Differences in cervical cancer screening and follow-up for black and white women in the United States. , 2020, Gynecologic oncology.

[6]  Daniel W. Goldberg,et al.  A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States , 2020, Gynecologic oncology.

[7]  N. Grabe,et al.  Accuracy and Efficiency of Deep-Learning–Based Automation of Dual Stain Cytology in Cervical Cancer Screening , 2020, Journal of the National Cancer Institute.

[8]  Y. You,et al.  DNA methylation for cervical cancer screening: a training set in China , 2020, Clinical Epigenetics.

[9]  D. Miglioretti,et al.  Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial , 2020 .

[10]  M. Doty,et al.  Primary Care Physicians' Role In Coordinating Medical And Health-Related Social Needs In Eleven Countries. , 2019, Health affairs.

[11]  Jasmin A. Tiro,et al.  Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment , 2019, JAMA network open.

[12]  A. Stroup,et al.  Determinants of Abnormal Cervical Cancer Screening Follow-Up And Invasive Cervical Cancer Among Uninsured and Underinsured Women in New Jersey , 2019, Journal of health care for the poor and underserved.

[13]  Jasmin A. Tiro,et al.  Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort , 2018, International journal of cancer.

[14]  M. Poljak,et al.  DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort , 2018, International journal of cancer.

[15]  C. Skinner,et al.  Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[16]  M. Phipps,et al.  Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[17]  E. J. Mayeaux,et al.  ASCCP Colposcopy Standards: Colposcopy Quality Improvement Recommendations for the United States , 2017, Journal of lower genital tract disease.

[18]  M. Schiffman,et al.  Why does cervical cancer occur in a state-of-the-art screening program? , 2017, Gynecologic oncology.

[19]  M. White,et al.  Cervical Cancer Screening and Incidence by Age: Unmet Needs Near and After the Stopping Age for Screening. , 2017, American journal of preventive medicine.

[20]  Y. Qiao,et al.  Pooled analysis on the necessity of random 4-quadrant cervical biopsies and endocervical curettage in women with positive screening but negative colposcopy , 2017, Medicine.

[21]  H. Hollema,et al.  Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3 , 2016, Clinical Epigenetics.

[22]  J. Cuzick,et al.  Human papillomavirus testing 2007–2012: Co‐testing and triage utilization and impact on subsequent clinical management , 2015, International journal of cancer.

[23]  Donald L Weaver,et al.  Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. , 2015, Journal of the National Cancer Institute.

[24]  Chengquan Zhao,et al.  Point-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years , 2015, Journal of Clinical Microbiology.

[25]  A. Priebe.  2012 cervical cancer screening guidelines and the future role of HPV testing. , 2013, Clinical obstetrics and gynecology.

[26]  V. Moyer,et al.  Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[27]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012 .

[28]  S. Wacholder,et al.  Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.

[29]  K. Stange.  The Problem of Fragmentation and the Need for Integrative Solutions , 2009, The Annals of Family Medicine.

[30]  Diane Solomon,et al.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. , 2007, American journal of obstetrics and gynecology.

[31]  E. Franco,et al.  Process of care failures in invasive cervical cancer: systematic review and meta-analysis. , 2007, Preventive medicine.

[32]  M. Manos,et al.  Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. , 2005, Journal of the National Cancer Institute.

[33]  Thomas C Wright,et al.  The 2001 Bethesda System terminology. , 2003, American family physician.

[34]  U. P. S. T. Force,et al.  Screening for cervical cancer: recommendations and rationale. , 2003, American family physician.

[35]  A. Moscicki,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2002, CA: a cancer journal for clinicians.

[36]  K. Nasseri,et al.  Increasing Cervical Cancer Screening Among Underserved Women in a Large Urban County Health System: Can It Be Done? What Does It Take? , 2002, Medical care.

[37]  J. Felix,et al.  Aberrant expression of E-cadherin in cervical intraepithelial neoplasia correlates with a false-negative Papanicolaou smear. , 2002, American journal of obstetrics and gynecology.

[38]  M. Plante,et al.  Guidelines on Adenocarcinoma in situ of the Cervix: Clinical Features and Review of Management: These guidelines have been prepared by the SOGC/GOC/SCC Policy and Practice Guideline Committee and were approved by the Council of the SOGC , 1999 .

[39]  Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. , 2016, Obstetrics and gynecology.

[40]  Roy Zhang,et al.  Multiple biopsies and detection of cervical cancer precursors at colposcopy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[42]  Hagerstoten.  American society for colposcopy and cervical pathology. , 1999, Journal of lower genital tract disease.